1. Home
  2. NRIX

as 11-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Founded: 2009 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 1.3B IPO Year: 2020
Target Price: $29.33 AVG Volume (30 days): 942.2K
Analyst Decision: Strong Buy Number of Analysts: 15
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.89 EPS Growth: N/A
52 Week Low/High: $5.65 - $29.56 Next Earning Date: 10-11-2024
Revenue: $56,424,000 Revenue Growth: -17.76%
Revenue Growth (this year): -27.41% Revenue Growth (next year): 7.17%

NRIX Daily Stock ML Predictions

Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ring Christine NRIX Chief Legal Officer Oct 1 '24 Sell $22.50 5,760 $128,017.33 24,892
Ring Christine NRIX Chief Legal Officer Sep 3 '24 Sell $25.27 9,050 $225,735.92 24,892
van Houte Hans NRIX Chief Financial Officer Aug 26 '24 Sell $25.22 20,000 $504,370.00 31,002
Ring Christine NRIX Chief Legal Officer Aug 26 '24 Sell $25.01 9,870 $246,842.78 24,892

Share on Social Networks: